Aim To report the incidence of endophthalmitis following the use of intravitreal injection of anti- vascular endothelial growth factor (anti VEGF) therapy. Methods In this retrospective study a total of 986 intravitreal bevacizumab injections were applied between January 2008 and April 2015 at the University Clinical Center Tuzla, Bosnia and Herzegovina (B&H). Since January 2012, a total of 55 intravitreal ranibizumab injections were applied and since October 2014, 60 intravitreal aflibercept injections were applied to patients. Results Two cases of endophthalmitis following intravitreal injection of bevaciuzumab occurred and none after ranibizumab or aflibercept. The overall incidence of clinical endophtahlmitis was 0.2%. Conclusion The results suggest that a low rate of endophthalmitis can be achieved by means of a protocol. This is a very important study as it is the first of this kind in B&H that documents the incidence of endophthalmitis after intravitreal application. Currently, bevacizumab in B&H is most frequently used intravitreal anti-vascular endothelial growth factor due to very low price.
El-Ashray M, Dhillon B. The article by Fintak et al. on the incidence of endophthalmitis related to intravitreal injections of bevacizumab and ranibizumab. Retina. 2009;720–1.
2.
Englander M, Chen T, Paschalis E, Miller J, Kim I. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates. Br J Ophthalmol. 2013;460–5.
3.
Cavalcante L, Cavalcante M, Murray T, Vigoda M, Pina Y, Decatur C, et al. Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol. 2010;519–24.
4.
Jonas J, Spandau U, Rensch F, Baltz V, Schlichtenbrede S, F. Infectious and noninfectious endophthalmitis afterintravitreal bevacizumab. J Ocul Pharmacol Ther. 2007;240–2.
5.
Diago T, Mccannel C, Bakri S, Pulido J, Edwards A, Pach J. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina. 2009;601–5.
6.
Mason J, White M, Feist R, Thomley M, Albert M, Persaud T, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina. 2008;564–7.
7.
Jonas J, Spandau U, Schlichtenbrede F. Shortterm complications of intravitreal injections of triamcinolone and bevacizumab. Eye (Lond). 2008;590–1.
8.
Fung A, Rosenfeld P, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;1344–9.
9.
Bhavsar A, Googe J, Jr, Stockdale C, Bressler N, Brucker A, et al. Risk of Endophthalmitis After Intravitreal Drug Injection When Topical Antibiotics Are Not Required: The Diabetic Retinopathy Clinical Research Network Laser-Ranibizumab-Triamcinolone Clinical Trials. Arch Ophthalmol. 2009;1581–3.
10.
Peyman G, Lee P, Seal D. Endophthalmitis: Diagnosis and Management. 2004;1–27.
11.
Schwartz S, Hw F, Iu S. Endophthalmitis after intravitreal injections. Expert Opin Pharmacother. 2009;1–8.
12.
Ramulu P, Do D, Corcoran K, Corcoran S, Robin A. Use of retinal procedures in medicare beneficiaries from 1997 to. Arch Ophthalmol. 2007;1335–40.
13.
Ferrara N, Hillan K, Novotny W, Bevacizumab. ), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;328–35.
14.
Rosenfeld P, Fung A, Puliafito C. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;336–9.
15.
Arevalo J, Fromow-Guerra J, Quiroz-Mercado H, Sanchez J, Wu L, Maia M, et al. Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: result from the Pan-American Collaborative Retina Study Group at 6-month follow up. Ophthalmology. 2007;743–50.
16.
Avery R, Bakri S, Blumenkrant M, Brucker A, Cunningham E, Jr D, et al. neovascular age-related macular degeneration: PIER Study year1. Am J Ophthalmol. 2008;239–48.
17.
Kernt M, Kampik A. Endophthalmitis: Pathogenesis, clinical presentation, management,and perspective. Clin Ophthalmol. 2010;121–35.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
